PRKAA1 and metabolic dysfunction-associated steatotic liver disease: These findings align with our previous studies demonstrating that the effects of FGF4 on both central glucose regulation and non-alcoholic fatty liver disease amelioration are mediated through FGFR-dependent AMPK activation in target cells26, 27, thereby establishing AMPK as a center molecular node within FGF4’s biological network.